Latest news with #JeffDormo
Yahoo
09-06-2025
- Business
- Yahoo
Evertis selects Honeywell Aclar Technology for pharmaceutical packaging
Evertis has selected Honeywell's Aclar film for its Evercare pharmaceutical brand, aiming to improve packaging solutions within the pharmaceutical sector. This decision is expected to ensure secure packaging for life-saving medications distributed globally. Honeywell Energy and Sustainability Solutions sustainability and decarbonisation president Jeff Dormo said: 'Honeywell developed Aclar barrier films to help empower our partners in the pharmaceutical industry to develop high-quality packaging materials that meet rigorous standards required in healthcare. 'Aclar has been safely used in the pharmaceutical industry for more than 50 years, and Evertis' selection of Aclar films supports our shared mission to help promote the safe and effective packaging of life-saving drugs, ultimately improving patient outcomes.' The Aclar films are claimed to have been designed to protect the efficacy of both prescription and over-the-counter medications. They are said to provide a superior moisture barrier, which is crucial for maintaining drug stability and extending shelf life. In addition to enhancing product integrity, Aclar films support the pharmaceutical industry's shift towards recyclable solutions. Their unique production methods facilitate easy separation and recycling, contributing to sustainability efforts. Evertis plans to utilise Aclar in the development of medical-grade polyethylene terephthalate (PET) packaging materials. PET is recognised for its lightweight and versatile properties, making it a popular choice across various industries. By integrating Aclar films into its PET packaging, Evertis aims to optimise manufacturing processes and reduce production costs. Honeywell will collaborate with Evertis to support the design, development, and launch of these new packaging materials. The PET products incorporating Aclar technology are anticipated to reach the market by 2025. Evertis Americas CSO Casimiro Sacchetti said: 'We are thrilled to partner with Honeywell to advance the next generation of pharmaceutical packaging. 'By combining Evertis' superior PET film and lamination expertise with Honeywell's unique Aclar barrier technology, we are now able to offer the pharmaceutical industry premium PET-based films with outstanding thermoforming, sealing, and optical properties - while also meeting sustainability credentials.' Furthermore, Honeywell said its Advanced Materials business will be rebranded as Solstice Advanced Materials following a tax-free spin-off to shareholders. This transition is projected to occur by early 2026, with the new company headquartered in Morris Plains, New Jersey. Solstice Advanced Materials will focus on chemicals and materials, providing advanced technologies in various sectors. These include refrigerants, medical and pharmaceutical packaging, and semiconductor components. "Evertis selects Honeywell Aclar Technology for pharmaceutical packaging" was originally created and published by Packaging Gateway, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Time of India
20-05-2025
- Business
- Time of India
Lupin partners with Honeywell for usage of propellant for inhalers
Lupin Ltd partners with Honeywell to incorporate 'Solstice Air' propellant in next-generation inhalers for asthma and COPD, aiming to reduce carbon emissions. This collaboration makes Lupin the first Indian pharma company to use Solstice Air at scale in pressurized metered-dose inhalers (pMDIs). Solstice Air offers a sustainable alternative, reducing greenhouse gas emissions by up to 99.9%. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Pharma major Lupin Ltd on Tuesday said it has partnered with Honeywell to use the latter's propellant ' Solstice Air ' to transform respiratory care through the development of next-generation inhalers . Designed for patients with asthma and chronic obstructive pulmonary disease ( COPD ), Honeywell 's 'Solstice Air' has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions, the company said in a statement. Lupin 's partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact ," Lupin CEO Vinita Gupta Energy and Sustainability Solutions Business President Jeff Dormo said,"Solstice Air can play a critical role in ensuring that Lupin life-saving devices provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions ."Lupin said it intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurised metered-dose inhalers (pMDIs).Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9 per cent, it added."By investigating the use of this innovative, nonflammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD," the company terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin, it added.
Malaysian Reserve
20-05-2025
- Business
- Malaysian Reserve
Lupin and Honeywell Move Forward Jointly with Plans for HFO Technology in Inhalers
Lupin is set to become first Indian company to fully integrate Honeywell's Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: (BLOOMBERG: LPCIN) NEW DELHI and MUMBAI, India, May 20, 2025 /PRNewswire/ — Global pharma major Lupin Limited (Lupin) announced today its plan to use Honeywell's Solstice® Air (HFO-1234ze cGMP) propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions. Lupin intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%.1 By investigating the use of this innovative, non-flammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD. 'Lupin's partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact,' said Vinita Gupta, CEO, Lupin. 'Solstice Air can play a critical role in ensuring that Lupin life-saving devices provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions,' said Jeff Dormo, a president in Honeywell's Energy and Sustainability Solutions business. 'By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions reducing practices that support industry advancements.' The terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin. References: 1Studies conducted by UNEP and American Lung Association About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit or follow us on LinkedIn About Honeywell Honeywell is an integrated operating company serving a broad range of industries and geographies around the world. Our business is aligned with three powerful megatrends – automation, the future of aviation and energy transition – underpinned by our Honeywell Accelerator operating system and Honeywell Forge IoT platform. As a trusted partner, we help organizations solve the world's toughest, most complex challenges, providing actionable solutions and innovations through our Aerospace Technologies, Industrial Automation, Building Automation and Energy and Sustainability Solutions business segments that help make the world smarter and safer as well as more secure and sustainable. For more news and information on Honeywell, please visit Solstice® is the registered trademark of Honeywell International Inc. Logo: View original content:
Yahoo
20-05-2025
- Business
- Yahoo
Lupin and Honeywell Move Forward Jointly with Plans for HFO Technology in Inhalers
Lupin is set to become first Indian company to fully integrate Honeywell's Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: (BLOOMBERG: LPCIN) NEW DELHI and MUMBAI, India, May 20, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) announced today its plan to use Honeywell's Solstice® Air (HFO-1234ze cGMP) propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions. Lupin intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%.1 By investigating the use of this innovative, non-flammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD. "Lupin's partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact," said Vinita Gupta, CEO, Lupin. "Solstice Air can play a critical role in ensuring that Lupin life-saving devices provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions," said Jeff Dormo, a president in Honeywell's Energy and Sustainability Solutions business. "By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions reducing practices that support industry advancements." The terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin. References: 1Studies conducted by UNEP and American Lung Association About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit or follow us on LinkedIn About Honeywell Honeywell is an integrated operating company serving a broad range of industries and geographies around the world. Our business is aligned with three powerful megatrends – automation, the future of aviation and energy transition – underpinned by our Honeywell Accelerator operating system and Honeywell Forge IoT platform. As a trusted partner, we help organizations solve the world's toughest, most complex challenges, providing actionable solutions and innovations through our Aerospace Technologies, Industrial Automation, Building Automation and Energy and Sustainability Solutions business segments that help make the world smarter and safer as well as more secure and sustainable. For more news and information on Honeywell, please visit Solstice® is the registered trademark of Honeywell International Inc. Logo: View original content: SOURCE Lupin Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
